{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:12:11Z","timestamp":1791396731239,"version":"4.3.3"},"update-to":[{"DOI":"10.1002\/14651858.cd002832.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T00:00:00Z","timestamp":1389744000000}}],"reference-count":88,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002832.pub3","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T11:01:59Z","timestamp":1389783719000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perazine for schizophrenia"],"prefix":"10.1002","volume":"2014","author":[{"given":"Stefan","family":"Leucht","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaningerstrasse 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Helfer","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaningerstrasse 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"Hartung","sequence":"additional","affiliation":[{"name":"University Hospital Duesseldorf; Institute for Legal Medicine; Moorenstr. 5 Duesseldorf Germany 40225"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,15]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD002832.pub3-BIB0002|cit1","first-page":"151","article-title":"Antipsychotic efficacy of trimipramine: double-blind comparison with a classical neuroleptic","volume":"30","author":"Bender","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0001|cit2","unstructured":"Bender S Olbrich H Hornstein C Sch\u00f6ne W Falkai P Trimipramine Study Group Antipsychotic efficacy of the antidepressant trimipramine: double-blind comparison with the phenothiazine perazine 6th World Congress of Biological Psychiatry Nice, France 75029586"},{"issue":"2","key":"10.1002\/14651858.CD002832.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2003-39043","article-title":"Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double-blind comparison with the phenothiazine perazine","volume":"36","author":"Bender","year":"2003","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1002\/14651858.CD002832.pub3-BIB0004|cit4","first-page":"780","article-title":"Schizoaffective disorders - testing of antipsychotic components of trimipramine","volume":"10","author":"Blaeser-Kiel","year":"1996","journal-title":"TW Neurologie Psychiatrie"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0005|cit5","first-page":"60","article-title":"not available","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Ackenheil","year":"1988"},{"issue":"1-2","key":"10.1002\/14651858.CD002832.pub3-BIB0007|cit6","first-page":"438","article-title":"A double-blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic-patients","volume":"32","author":"Dieterle","year":"1987","journal-title":"International Journal of Neuroscience"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0006|cit7","unstructured":"Dieterle DM Albus M Blanke E Eben E Klein H M\u00fcller-Spahn R\u00fcther E A double-blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients 4th World Congress of Biological Psychiatry; 1989 Sept 8-13; Philadelphia, USA 1989"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0008|cit8","first-page":"340","article-title":"Comparison of zotepine and perazine in schizophrenia","volume":"96 Suppl 1","author":"Dieterle","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-1000730","article-title":"Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics","volume":"59 Suppl 1","author":"Dieterle","year":"1991","journal-title":"Fortschritte der Neurologie und Psychiatrie"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-2007-1000732","article-title":"Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double-blind controlled study","volume":"59","author":"M\u00fcller-Spahn","year":"1991","journal-title":"Fortschritte der Neurologie und Psychiatrie"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0012|cit11","first-page":"85","article-title":"Clinical relevance of the test dose model for drug choice and response in acute schizophrenia","volume":"25","author":"Klimke","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0011|cit12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-2007-1014337","article-title":"Initial improvement as a criterion for drug choice in acute schizophrenia","volume":"26","author":"Klimke","year":"1993","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0013|cit13","first-page":"65","article-title":"not available","volume-title":"Therapie mit Neuroleptika - Perazin","author":"R\u00fcther","year":"1988"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0014|cit14","unstructured":"K\u00fcstner U Renfordt E M\u00fcller-Oerlinghausen B Relationship between neuroleptic medication, handwriting area and therapeutic response Proceedings of the 14. CINP-Congress, Florence 1984"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-2007-1017282","article-title":"Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?","volume":"19","author":"Meya","year":"1986","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0016|cit16","first-page":"55","article-title":"not available","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Renfordt","year":"1988"},{"issue":"9","key":"10.1002\/14651858.CD002832.pub3-BIB0018|cit17","first-page":"530","article-title":"A double-blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients","volume":"53","author":"Schmidt","year":"1982","journal-title":"Nervenarzt"},{"issue":"8","key":"10.1002\/14651858.CD002832.pub3-BIB0019|cit18","first-page":"910","article-title":"A double-blind comparison of the antipsychotic efficacy of perazine compared to haloperidol","volume":"32","author":"Schmidt","year":"1982","journal-title":"Arzneimittel-Forschung"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0017|cit19","first-page":"40","article-title":"not available","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Sch\u00fcssler","year":"1988"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0020|cit20","unstructured":"Samochowiec J Tybura P Wysiecka JP Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1734-1140(12)70848-4","article-title":"Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients","volume":"64","author":"Tybura","year":"2012","journal-title":"Pharmacological Reports"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-1000731","article-title":"Zotepine versus perazine in paranoid schizophrenia: a double-blind controlled trial of antipsychotic efficacy","volume":"59 Suppl 1","author":"Wetzel","year":"1991","journal-title":"Fortschritte der Neurologie und Psychiatrie"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0924-977X(99)80361-7","article-title":"Evaluation of dry mouth and its treatment in the course of antipsychotic pharmacotherapy","volume":"9 Suppl 5","author":"Bender","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0924-977X(99)80359-9","article-title":"Effect of olanzapine on salivation is less prominent than predicted by its in vitro muscarinic binding profile","volume":"9 Suppl 5","author":"Czekalla","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD002832.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0006-2952(92)90015-B","article-title":"Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes","volume":"44","author":"Fischer","year":"1992","journal-title":"Biochemical Pharmacology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2007-1019594","article-title":"Predictors of the course of schizophrenic diseases under neuroleptic long-term medication","volume":"14","author":"Gaebel","year":"1981","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0027|cit27","unstructured":"Gaebel W Oschinsky AM Low-dose neuroleptic treatment in neurotic disorders Abstract book of the the 15. CINP-Congress San Juan, Puerto Rico 1986"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-2007-1017019","article-title":"Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine","volume":"21","author":"Gaebel","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0029|cit29","unstructured":"Gaebel W Schley J M\u00fcller-Oerlinghausen B Early pharmacokinetic and clinical data as predictors of response to acute antipsychotic treatment with perazine Abstract book of the 15. CINP-Congress at San Juan, Puerto Rico 1986"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0030|cit30","first-page":"43","article-title":"Early treatment effects of perazine as predictor of acute antipsychotic treatment outcome in schizophrenics","volume":"59 Suppl 5","author":"Gaebel","year":"1986","journal-title":"Acta Pharmacolgica Toxicologica"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02190342","article-title":"Facial expression and emotional face recognition in schizophrenia and depression","volume":"242","author":"Gaebel","year":"1992","journal-title":"Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.121.2.179","article-title":"Clinical trial of a potentiated diketopiperazine derivative as a psychopharmacological agent for the treatment of psychotic patients","volume":"121","author":"Gerson","year":"1964","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000026619","article-title":"The influence of clozapine and typical neuroleptics on information processing of the central nervous sstem under cinical conditions in schizophrenic disorders: implications for fitness to drive","volume":"40","author":"Grabe","year":"1999","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0924-977X(99)80290-9","article-title":"Quality of life of schizophrenic patients treated with classic and \"old\" atypical neuroleptics","volume":"9 Suppl 5","author":"Jarema","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Jockers-Scher\u00fcbl MC Godemann F Pietzcker A Paroxetine augmentation of neuroleptic treatment in chronic schizophrenia: An open pilot study Proceedings of the 20th Symposium of the AGNP, N\u00fcrnberg 1997","DOI":"10.1016\/S0924-977X(97)88668-3"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0036|cit36","first-page":"1512","article-title":"not available","volume":"62","author":"Kemperdick","year":"1967","journal-title":"Medizinische Klinik"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0037|cit37","first-page":"51","article-title":"not available","volume-title":"Therapie mit Neuroleptika-Perazin","author":"Kuhs","year":"1988"},{"issue":"3","key":"10.1002\/14651858.CD002832.pub3-BIB0038|cit38","first-page":"285","article-title":"Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores","volume":"11","author":"Loza","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD002832.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0924-977X(03)92108-0","article-title":"Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia","volume":"13","author":"Mazurek","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD002832.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000103906","article-title":"Perazine and carbamazepine in comparison to olanzapine in schizophrenia","volume":"55","author":"Ohlmeier","year":"2007","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0041|cit41","first-page":"315","article-title":"Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug","volume":"229","author":"Pietzcker","year":"1981","journal-title":"Archives of Psychiatry and Neurological Sciences"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-2007-1017430","article-title":"The outpatient clinic for patients under chronic lithium treatment as a phase-IV research tool","volume":"17","author":"Pietzcker","year":"1984","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2007-1019489","article-title":"Prediction and evaluation criteria in perazine therapy of acute schizophrenics: Methodological considerations, sample population, and research variables","volume":"16","author":"Rein","year":"1983","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-2007-1019490","article-title":"Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results","volume":"16","author":"Schied","year":"1983","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0045|cit45","first-page":"721","article-title":"Assessment of neuroleptic therapy in schizophrenic patients admitted to a university psychiatric department","volume":"59","author":"Schmidt","year":"1988","journal-title":"Nervenarzt"},{"issue":"1","key":"10.1002\/14651858.CD002832.pub3-BIB0046|cit46","first-page":"24","article-title":"Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia","volume":"23","author":"Terminska","year":"1989","journal-title":"Psychatria Polska"},{"issue":"2-3","key":"10.1002\/14651858.CD002832.pub3-BIB0047|cit47","first-page":"94","article-title":"Orthostatic challenge during neuroleptic test dose: A possible predictor of short-term outcome","volume":"30","author":"Volz","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0048|cit48","first-page":"256","article-title":"not available","volume":"67","author":"Wetterling","year":"1996","journal-title":"Nervenarzt"},{"issue":"2","key":"10.1002\/14651858.CD002832.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF02244218","article-title":"Savoxepine: Invalidation of an \"atypical\" neuroleptic response pattern predicted by animal models in an open clinical trial with acute schizophrenic patients","volume":"103","author":"Wetzel","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0050|cit50","unstructured":"Alderson P Green S Higgins JPT Cochrane Reviewers' Handbook 4.2.2 [updated December 2003] The Cochrane Library 2004"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD002832.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT Statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0053|cit53","volume-title":"Psychiatrische Pharmakotherapie","author":"Benkert","year":"1996"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD002832.pub3-BIB0055|cit55","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.316.7126.221","article-title":"Meta-analysis: Unresolved issues and future developments","volume":"16","author":"Davey Smith","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0058|cit58","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD002832.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002832.pub3-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD002832.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The Global Assessment Scale","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0065|cit65","first-page":"534","article-title":"not available","volume":"197","author":"Enss","year":"1958","journal-title":"Archiv f\u00fcr Neurologie und Nervenkrankheiten"},{"issue":"7","key":"10.1002\/14651858.CD002832.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0067|cit67","first-page":"74","article-title":"not available","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Grohmann","year":"1988"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0069|cit69","article-title":"Clinical Global Impressions","volume-title":"Manual for the ECDEU Assessment Battery, 2. Rev ed","author":"Guy","year":"1970"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0071|cit71","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD002832.pub3-BIB0072|cit72","unstructured":"Hippius H Long-term pharmacotherapy of schizophrenia Proceedings of the II International Conference of the Manfred Sakel Foundation New York CC Page and Co 1962"},{"issue":"1","key":"10.1002\/14651858.CD002832.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British journal of haematology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0075|cit75","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0076|cit76","first-page":"463","article-title":"not available","volume":"9","author":"Kr\u00fcger","year":"1963","journal-title":"Medizinische Welt"},{"issue":"2-3","key":"10.1002\/14651858.CD002832.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD002832.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment? A review","volume":"39","author":"Marwaha","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0082|cit82","first-page":"9","article-title":"not available","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Menge","year":"1988"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0085|cit85","first-page":"3","article-title":"Brain dopamine receptors","volume":"32","author":"Seeman","year":"1981","journal-title":"Pharmacological Review"},{"key":"10.1002\/14651858.CD002832.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD002832.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD002832.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002832.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T10:35:21Z","timestamp":1713004521000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002832.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,15]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002832.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,15]]}}}